Robert E. Landry, EVP Finance CFO at REGENERON PHARMACEUTICALS, INC. (REGN), sold 11,281 shares at $729.76 ($8.3M) on 2022-04-11, disclosed to the SEC on 2022-04-11.
Open-market sale of $8.3M REGN by EVP Finance CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $716.09 | 1,175 | $841K | 10.2% |
| 2 | $724.33 | 16 | $12K | 0.1% |
| 3 | $728.77 | 30 | $22K | 0.3% |
| 4 | $729.67 | 16 | $12K | 0.1% |
| 5 | $733.38 | 44 | $32K | 0.4% |
| 6 | $735.12 | 43 |
| $32K |
| 0.4% |
| 7 | $736.21 | 4,586 | $3.4M | 40.8% |
| 8 | $736.21 | 1,552 | $1.1M | 13.8% |
| 9 | $739.02 | 29 | $21K | 0.3% |
| 10 | $740.98 | 28 | $21K | 0.3% |
| 11 | $743.71 | 32 | $24K | 0.3% |
| 12 | $744.52 | 56 | $42K | 0.5% |
| 13 | $745.27 | 31 | $23K | 0.3% |
| 14 | $729.76 | 74 | $54K | 0.7% |
| 15 | $729.76 | 74 | $54K | 0.7% |
| 16 | $731.60 | 37 | $27K | 0.3% |
| 17 | $732.56 | 22 | $16K | 0.2% |
| 18 | $733.52 | 1,226 | $899K | 10.9% |
| 19 | $733.52 | 1,226 | $899K | 10.9% |
| 20 | $734.53 | 75 | $55K | 0.7% |
| 21 | $734.53 | 75 | $55K | 0.7% |
| 22 | $735.36 | 149 | $110K | 1.3% |
| 23 | $735.36 | 149 | $110K | 1.3% |
| 24 | $736.61 | 189 | $139K | 1.7% |
| 25 | $736.61 | 189 | $139K | 1.7% |
| 26 | $737.89 | 22 | $16K | 0.2% |
| 27 | $738.63 | 68 | $50K | 0.6% |
| 28 | $738.63 | 68 | $50K | 0.6% |
| Total | $733.47 avg | 11,281 | $8.3M | 100% |
| Filing → |
| REGN | SELL | 2023-08-25 | $188K | — | Filing → |
| REGN | SELL | 2023-03-29 | $1.8M | — | Filing → |
| REGN | SELL | 2023-02-07 | $2.1M | — | Filing → |